One of the major challenges in modern drug development is the poor aqueous solubility of many drug candidates. Nanoparticle formulations are an attractive solution to increase the bioavailability of drugs with low aqueous solubility. Dissolution testing is one of the most important methods used to characterize the expected in vivo bioavailability under in vitro conditions. Thus, an efficient dissolution method is necessary during the nanoparticle development process to facilitate the selection of lead formulations with an expected higher bioavailability. It is equally important for quality control purposes during later stages of the product life cycle. Furthermore, automation of dissolution testing with nanoparticles facilitates faster method transfer to the quality control lab.
In this webinar, we will introduce you to the Agilent NanoDis System. Designed in collaboration with Dr. Emre Türeli from nanoparticle manufacturer MyBiotech GmbH, the NanoDis System enables R&D formulation chemists to deliver new formulations into manufacturing faster, and also allows manufacturing teams to deliver consistent batches of QC-released drug products ready for commercial sale—all in an automated and compliant manner.